Childhood cancer: A growing concern - What you need to know
Childhood cancer affects children under 18 and requires specialized treatment. Common types include leukemia, brain and ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
IN8bio, Inc: IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...
IN8bio reports promising phase 1 results for leukemia therapy
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
Too Old to Operate21h
Impact of Genomic and Clinical Ontogeny on AML Outcomes
Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...
IN8bio presented Phase 1 data on INB-100 at 2025 TCT
IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...